Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET
Company Participants
Lisa Miller - Senior Director, IR
Richard Hawkins - CEO & Chairman
John McKew - Chief Scientific Officer & President
David Karpf - Chief Medical Officer
Lori Lawley - CFO & Principal Accounting Officer
Conference Call Participants
Avraham Novick - Cantor Fitzgerald & Co.
Yasmeen Rahimi - Piper Sandler & Co.
Catherine Novack - JonesTrading Institutional Services
Edward White - H.C. Wainwright & Co.
Operator
Good afternoon, and welcome to Lumos Pharma's First Quarter 2022 Results & Clinical Update Conference Call. [Operator Instructions].
As a reminder, this conference call is being recorded. I'd now like to turn the call over to Lisa Miller, Senior Director of Investor Relations. Please go ahead.
Lisa Miller
Thank you, Operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC.
The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release we issued this afternoon and in our Form 8-K, which may be accessed from the Investors page of the company's website.
Speaking on today's call will be Rick Hawkins, CEO and Chairman; John McKew, our President and Chief Scientific Officer; Dr. David Karpf, our Chief Medical Officer; and Lori Lawley, our Chief Financial Officer.
I will now turn the call over to Rick.
Richard Hawkins
Thank you, Lisa. Good afternoon, everyone, and thank you for joining us on today's call. Now after the market closed today, we issued a press release announcing our financial results for the 2022 first quarter and detailing our progress advancing our clinical programs for the treatment of patients with idiopathic or moderate pediatric growth hormone deficiency or PGHD using our daily oral therapeutic LUM-201.
On today's call, I'll provide a brief update on our LUM-201 clinical trials and other developments before turning it over to John, who will discuss our new collaboration with Massachusetts General Hospital for an investigator-initiated Phase II pilot trial. Then David will discuss an update to our clinical team. And finally, Lori will review our financial results.